Enasidenib Mesylate
CAS 1650550-18-0Small Molecule
Overview
Enasidenib Mesylate is an inhibitor of the mutant isocitrate dehydrogenase 2 (IDH2) enzyme. It is used in the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) who harbor IDH2 mutations.
Therapeutic areas
OncologyHematology
Verified Supplier Partner
Do you supply Enasidenib Mesylate? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.